Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release

Drug Delivery

Volumn 22, Issue 3, 2015, Pages 389-399

  Wang, Ke ^a   Zhang, Xiaofeng ^a   Zhang, Lihong ^a   Qian, Lili ^a   Liu, Chang ^a   Zheng, Jiajun ^a   Jiang, Yanyan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Conjugates; Doxorubicin; Gliomas; Implants; Polymer

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; DENDRIMER; DOXORUBICIN; DRUG CARRIER; MACROGOL; POLYAMIDOAMINE; ANTINEOPLASTIC ANTIBIOTIC; ARGINYL-GLYCYL-ASPARTIC ACID; DELAYED RELEASE FORMULATION; DRUG IMPLANT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEG-PAMAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABLE IMPLANT; CANCER THERAPY; CONJUGATE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VISCOSITY; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG IMPLANT; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; NEOPLASMS, EXPERIMENTAL; TIME FACTOR; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DENDRIMERS; DOXORUBICIN; DRUG CARRIERS; DRUG IMPLANTS; DRUG LIBERATION; MALE; MICE, INBRED ICR; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84930456052     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.895457     Document Type: Article

References (43)

1. Anonymous. (1996). Gliadel wafer recommended for approval as treatment for brain cancer by FDAS Oncologic Drugs Advisory Committee. Drug News Perspect 9:292.
2. Aqil F, Jeyabalan J, Kausar H, et al. (2012). Multi-layer polymeric implants for sustained release of chemopreventives. Cancer Lett 326: 33-40.
3. Arias JL. (2011). Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem 11:1-17.
4. Badie B, Schartner JM. (2000). Flow cytometric characterization of tumor-Associated macrophages in experimental gliomas. Neurosurgery 46:957-61.
5. Beutler AS, Banck MS, Wedekind D, et al. (1999). Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Hum Gene Ther 10:95-101.
6. Bragagni M, Mennini N, Ghelardini C, et al. (2012). Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. Pharm Pharm Sci 15:184-96.
7. Cai W, Niu G, Chen X. (2008). Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14:2943-73.
8. Fu YJ, Shyu SS, Su FH, et al. (2002). Development of biodegradable co-poly(D, L-lactic/glycolic acid) microspheres for the controlled release of 5-FU by the spray drying method. Colloid Surface B 25: 269-79.
9. Haaga JR, Exner AA, Wang Y, et al. (2005). Combined tumor therapy by using radiofrequency ablation and 5-FU-laden polymer implants: evaluation in rats and rabbits. Radiology 237:911-18.
10. Herrmann S, Winter G, Mohl S, et al. (2007). Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Control Release 118:161-8.
11. Holy CE, Dang SM, Davies JE, et al. (1999). In vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam. Biomaterials 20: 1177-85.
12. Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-90.
13. Jiang Z, Sun C, Yin Z, et al. (2012). Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems. Int J Nanomed 7:2019-31.
14. Koocheki S, Madaeni SS, Niroomandi P. (2011). Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride. Saudi Pharm J 19:255-62.
15. Lesniak MS, Upadhyay U, Goodwin R, et al. (2005). Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25:3825-31.
16. Li Y, He H, Jia X, et al. (2012). A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33: 3899-908.
17. Liu J, Shapiro JI. (2003). Endocytosis and signal transduction: basic science update. Biol Res Nurs 5:117-28.
18. Mesnukul A, Yodkhum K, Mahadlek J, et al. (2010). Characterization of indomethacin release from polyethylene glycol tablet fabricated with mold technique. Indian J Pharm Sci 72:92-100.
19. Negrin CM, Delgado A, Llabres M, et al. (2004). Methadone implants for methadone maintenance treatment. In vitro and in vivo animal studies. J Control Release 95:413-21.
20. Onishi H, Takahashi M, Machida Y. (2005). PLGA implant tablet of ketoprofen: comparison of in vitro and in vivo releases. Biol Pharm Bull 28:2011-15.
21. Ojugo A, McSheehy P, McIntyre D, et al. (1999). Measurement of the extracellular pH of solid tumors in mice by magnetic resonance spectroscopy: a comparison of exogenous F-19 and P-31 probes. Nmr Biomed 12:495-504.
22. Paun IA, Moldovan A, Luculescu CR, et al. (2011). Biocompatible polymeric implants for controlled drug delivery produced by MAPLE. Appl Surf Sci 257:10780-8.
23. Puvanakrishnan P, Park J, Chatterjee D, et al. (2012). In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int J Nanomed 7:1251-8.
24. Ranganath SH, Fu Y, Arifin DY, et al. (2010). The use of submicron/ nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials 31:5199-207.
25. Santovena A, Alvarez-Lorenzo C, Llabres M, et al. (2009). hGH release from directly compressed hGH-PLGA biodegradable implantable tablets: influence of physicomechanical factors. Eur Polym J 45: 2830-8.
26. Shikanov A, Shikanov S, Vaisman B, et al. (2008). Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant. Int J Pharm 358:114-20.
27. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics. Ca-Cancer J Clin 62:10-29.
28. Siegel SJ, Kahn JB, Metzger K, et al. (2006). Effect of drug type on the degradation rate of PLGA matrices. Eur J Pharm Biopharm 64: 287-93.
29. Sivak WN, Pollack IF, Petoud S, et al. (2008). LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas. Acta Biomater 4:852-62.
30. Stupp R, Hegi ME, van den Bent MJ, et al. (2006). Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist 11:165-80.
31. Temming K, Schiffelers RM, Molema G, et al. (2005). RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 8:381-402.
32. Takahashi M, Onishi H, Machida Y. (2004). Development of implant tablet for a week-long sustained release. J Control Release 100:63-74.
33. Vannucci L, Falvo E, Fornara M, et al. (2012). Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int J Nanomed 7:1489-509.
34. Voulgaris S, Partheni M, Karamouzis M, et al. (2002). Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol-Canc 25:60-4.
35. Wang CC, Li J, Teo CS, et al. (1999). The delivery of BCNU to brain tumors. J Control Release 61:21-41.
36. Wang JX, Wang ZH, Chen JF, et al. (2008). Direct encapsulation of water-soluble drug into silica microcapsules for sustained release applications. Mater Res Bull 43:3374-81.
37. Wang Q, Han Y, Jiang T, et al. (2011). MR Imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrintargeted ultrasmall superparamagnetic iron oxide. Eur Radiol 21: 1016-25.
38. Weinberg BD, Ai H, Blanco E, et al. (2007). Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A 81:161-70.
39. Zhang C, Xie X, Liang S, et al. (2012). Mono-dispersed high magnetic resonance sensitive magnetite nanocluster probe for detection of nascent tumors by magnetic resonance molecular imaging. Nanomed- Nanotechnol Biol Med 8:996-1006.
40. Zhang L, Zhu S, Qian L, et al. (2011). RGD-modified PEG-PAMAMDOX conjugates: in vitro and in vivo studies for glioma. J Eur J Pharm Biopharm 79:232-40.
41. Zhu S, Hong M, Tang G, et al. (2010a). Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 31:1360-71.
42. Zhu S, Hong M, Zhang L, et al. (2010b). PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res 27:161-74.
43. Zhu S, Qian L, Hong M, et al. (2011). RGD-modified PEGPAMAM- DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Adv Mater 23: H84-9.